Developing Story
Hikma v. Amarin – Pharma Patent Pleading Standard (SCOTUS, 2026)
Hikma v. Amarin is a significant pharmaceutical patent case before the Supreme Court addressing what plaintiffs must plead to establish induced infringement when a generic drug uses a Hatch-Waxman skinny label. The outcome will materially affect generic drug market entry strategy and brand patent enforcement.
Importance: 78%Confidence: 82%Mentions: 1Updated: April 30, 2026
## Hikma v. Amarin – Pharma Patent Pleading Standard (SCOTUS, 2026)
A pending or recently argued Supreme Court case addressing the pleading standard for induced patent infringement claims under 35 U.S.C. § 271(b) in the context of pharmaceutical skinny-label approvals under the Hatch-Waxman Act.
### Legal Background
- The **Hatch-Waxman Act Section VIII pathway** ("skinny label") allows generic drug manufacturers to obtain FDA approval for unpatented indications only, avoiding reference to patented uses
- **35 U.S.C. § 271(b)** imposes liability on any party who "actively induces" infringement of a patent
- The tension between these two provisions has been a persistent source of litigation in pharmaceutical patent law
### The Case
- **Hikma Pharmaceuticals** sought FDA approval for a generic version of Amarin's drug using a skinny label, excluding the patented cardiovascular indication
- **Amarin** alleged that Hikma's marketing and labeling nonetheless actively induced physicians to prescribe the drug for the patented use
- The central dispute: what must a plaintiff plead — and ultimately prove — to establish active inducement when a generic uses a skinny label? (IPWatchdog, April 28, 2026)
### Significance
- The case could resolve a circuit split or clarify the pleading standard for induced infringement in the skinny-label context
- A ruling favoring Amarin would make it easier for brand manufacturers to challenge skinny-label generics
- A ruling favoring Hikma would strengthen the Section VIII pathway and facilitate generic competition
- Affects billions of dollars in pharmaceutical patent litigation strategy and generic drug market entry timing
### Practitioner Implications
- Patent litigators in pharma must monitor the pleading threshold the Court establishes
- Generic manufacturers structuring skinny-label strategies face uncertainty pending the decision
- Brand companies may revisit litigation strategies for off-label use inducement claims